Expertise in
6
conditions

Wilfried A. Schroyens

Uza
Antwerpen, VLG, BE 
Expertise in
6
conditions
Uza
Antwerpen, VLG, BE 

Overview

Wilfried Schroyens practices practicing medicine in Antwerpen, Belgium.

Mr. Schroyens is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Wilms Tumor, Agranulocytosis, Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

UZA
Antwerpen, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Brentuximab
Study Phase: Phase 2
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
Enrollment Status: Terminated
Publish Date: September 08, 2021
Intervention Type: Other, Biological
Study Drug: Mesenchymal Stem Cells
Study Phase: Phase 2
View 2 Less Clinical Trials

41 Total Publications

Teclistamab as Successful Treatment of Relapsed TEMPI Syndrome.
Teclistamab as Successful Treatment of Relapsed TEMPI Syndrome.
Journal: The New England journal of medicine
Published: January 08, 2025

Frequently Asked Questions about Wilfried A. Schroyens

Is Wilfried A. Schroyens a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Wilfried A. Schroyens is classified as an Advanced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Wilfried A. Schroyens participate in research or clinical trials?

Yes. Wilfried A. Schroyens has published 41 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Wilfried A. Schroyens's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schroyens's expertise for a condition
ConditionClose
      View All 26 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile